Clinical trial
Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and…
NCT00323622 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00323622 |
|---|---|
| Title | Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine |
| Official title | An Open Study for a 2-year Period to Confirm the Safety and Immunogenicity of the Candidate Malaria Vaccine RTS,S/AS02A in Mozambican Children Aged 1 to 4 Years at the Time of First Vaccine Dose. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Biological, Drug |
| Interventions | GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049, Engerix™-B, Hiberix®, Prevnar™, sulfadoxine-pyrimethamine, amodiaquine |
| Enrollment | 1,737 |
| Start date | Apr 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | May 9, 2006 |
| Last update posted | Dec 9, 2016 |
| Countries | Mozambique |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: